INT182339

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.68
First Reported 2005
Last Reported 2010
Negated 4
Speculated 0
Reported most in Body
Documents 18
Total Number 20
Disease Relevance 16.60
Pain Relevance 0.42

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (Ms4a1)
Anatomy Link Frequency
B-cell 7
lymphocytes 2
marginal zone 1
Ms4a1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 109 97.24 Very High Very High Very High
rheumatoid arthritis 41 79.96 Quite High
cytokine 14 79.84 Quite High
headache 26 73.52 Quite High
methotrexate 12 57.48 Quite High
Arthritis 24 51.48 Quite High
spinal inflammation 13 49.92 Quite Low
dexamethasone 12 27.28 Quite Low
intrathecal 4 21.52 Low Low
fibrosis 34 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Chronic Lymphoid Leukemia 248 99.96 Very High Very High Very High
Lymphatic System Cancer 813 99.70 Very High Very High Very High
Disease 398 99.64 Very High Very High Very High
Malignant Neoplastic Disease 47 99.48 Very High Very High Very High
B-cell Chronic Lymphocytic Leukemia 96 98.64 Very High Very High Very High
Genetic Translocation 8 98.32 Very High Very High Very High
Infection 262 98.08 Very High Very High Very High
INFLAMMATION 121 97.50 Very High Very High Very High
Multiple Myeloma 32 95.28 Very High Very High Very High
Apoptosis 50 93.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This CDC lysis correlates in part with the level of CD20 expression but may also be dependent on the interaction with complement regulatory proteins (Golay et al 2000, 2001; Treon et al 2001).
Gene_expression (expression) of CD20
1) Confidence 0.68 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 0.59 Pain Relevance 0.11
The immunophenotype of marginal lymphomas is distinct from other small lymphocytic lymphomas: the antigen profile for the marginal zone lymphomas include CD19, CD20, CD22 positive and CD5, CD10, CD23, and CD11C negative.
Neg (negative) Gene_expression (negative) of CD20 in marginal zone associated with b-cell chronic lymphocytic leukemia and lymphatic system cancer
2) Confidence 0.68 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 1.16 Pain Relevance 0
The gene for CD20 (MS4A1) is switched on at the pre-B-cell stage of B-cell development, expressed throughout B-cell maturation, and lost during final maturation to plasma cells (Cartron et al 2004).
Gene_expression (expressed) of MS4A1 in B-cell
3) Confidence 0.68 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 1.00 Pain Relevance 0
CD20 is expressed on the B-cell at a high density in excess of 100,000 copies per cell but does appear to vary by histologic subtype.
Gene_expression (expressed) of CD20 in B-cell
4) Confidence 0.68 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 0.81 Pain Relevance 0
In another model using rituxiamb sensitive and resistant cell clones, surface CD20 expression has been demonstrated to be diminished in resistant line (Czuczman et al 2004).
Gene_expression (expression) of CD20
5) Confidence 0.68 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 0.14 Pain Relevance 0
The antigen profile includes CD20, CD19 and CD5 positive, and is BCL-2 and cyclin D1 positive but usually CD10 and BCL-6 negative.
Gene_expression (positive) of CD20
6) Confidence 0.59 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 1.43 Pain Relevance 0
The gene for CD20 (MS4A1) is switched on at the pre-B-cell stage of B-cell development, expressed throughout B-cell maturation, and lost during final maturation to plasma cells (Cartron et al 2004).
Gene_expression (expressed) of CD20 in B-cell
7) Confidence 0.59 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 1.00 Pain Relevance 0
CD20 (membrane-spanning 4-domain, group A, member 1) is a nonglycosylated protein of 33 to 35 kDa expressed on the cell surface of human B lymphoctyes.
Gene_expression (expressed) of CD20
8) Confidence 0.53 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 1.29 Pain Relevance 0
In addition, CD20 expression may change during the disease course (Robillard et al 2003; Bergua et al 2008), and it may be worthwhile occasionally repeating diagnostic evaluation.
Gene_expression (expression) of CD20 associated with disease
9) Confidence 0.43 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 0.86 Pain Relevance 0.03
Because all WM cells eventually express CD20, rituximab was explored and initial trials showed some efficacy of the drug.
Gene_expression (express) of CD20 associated with disease
10) Confidence 0.43 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.06 Pain Relevance 0
However, in CLL, CD20 is expressed to a lesser extent than in normal B-cells or other B-NHL and, furthermore, soluble CD20 may hamper the efficacy of rituximab.
Gene_expression (expressed) of CD20 in B-cells associated with chronic lymphoid leukemia and lymphatic system cancer
11) Confidence 0.43 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.21 Pain Relevance 0
Additionally, CD20 is not shed, and there is no soluble form of CD20 that could interfere with therapeutic antibodies.
Neg (not) Gene_expression (shed) of CD20
12) Confidence 0.37 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 0.33 Pain Relevance 0
When the two clusters of the SpA cohort were compared, the cluster with higher CRP and ESR was found to show a significant increase of the following histological parameters: vascularity (P = 0.001), inflammatory infiltration (P < 0.001), lymphoid aggregates (P = 0.027), plasma cells (P = 0.001), PMNs (P < 0.001), CD3+ lymphocytes (P < 0.001), and CD20+ lymphocytes (P = 0.007).


Gene_expression (lymphocytes) of CD20 in lymphocytes associated with inflammation
13) Confidence 0.23 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065336 Disease Relevance 0.60 Pain Relevance 0.14
Subsequent visualization was done as described for Helicobacter, CD3 and CD20 staining.
Gene_expression (staining) of CD20
14) Confidence 0.20 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2989923 Disease Relevance 0.07 Pain Relevance 0
Subsequent visualization was done as described for Helicobacter, CD3 and CD20 staining.
Gene_expression (staining) of CD20
15) Confidence 0.20 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2989923 Disease Relevance 0.08 Pain Relevance 0
Image analysis revealed that from 9 weeks of infection onwards, lymphocytic aggregates and follicles in these animals contained at least 60% B cells (CD20 positive and CD3 negative) (Figure 2I and Figure 2J).
Neg (negative) Gene_expression (positive) of CD20 in B cells associated with infection
16) Confidence 0.20 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2989923 Disease Relevance 0.89 Pain Relevance 0.14
Both are directed against CD20, albeit not against the same epitope.
Neg (not) Gene_expression (directed) of CD20
17) Confidence 0.12 Published 2007 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC1914264 Disease Relevance 0.75 Pain Relevance 0
The difference in clinical results between rituximab, a chimeric human-mouse anti-CD20, and alemtuzumab may be related to the relative expression of CD20 and CD52 on malignant lymphocytes; the level of CD20 expression in patients with B-CLL is low, in comparison with other B-cell lymphomas and normal B-cells (Rossmann et al 2001).
Gene_expression (expression) of CD20 in B-cell associated with chronic lymphoid leukemia, malignant neoplastic disease and lymphatic system cancer
18) Confidence 0.07 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727786 Disease Relevance 0.97 Pain Relevance 0
These include: a) variable expression of CD20 and CD52 on CLL cells of individual patients; b) synergistic activity in anatomic compartments such as lymphnode sites (where rituximab is expected to be more effective), versus marrow, (better clearance of malignant lymphocytes with alemtuzumab); c) engagement of distinct intracellular signaling pathways resulting in apoptotic cell death.
Gene_expression (expression) of CD20 in lymphocytes associated with chronic lymphoid leukemia, malignant neoplastic disease, apoptosis and death
19) Confidence 0.07 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727786 Disease Relevance 1.46 Pain Relevance 0
The difference in clinical results between rituximab, a chimeric human-mouse anti-CD20, and alemtuzumab may be related to the relative expression of CD20 and CD52 on malignant lymphocytes; the level of CD20 expression in patients with B-CLL is low, in comparison with other B-cell lymphomas and normal B-cells (Rossmann et al 2001).
Gene_expression (expression) of CD20 in B-cell associated with chronic lymphoid leukemia, malignant neoplastic disease and lymphatic system cancer
20) Confidence 0.07 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727786 Disease Relevance 0.91 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox